The natural history of PRV is characterized by a prolonged period of m
yeloproliferation chiefly affecting the red cell series. It can be con
trolled by venesection and cytotoxic agents. In this case report the p
atient declined further 'standard' chemotherapy to control his disease
and the use of relatively low doses of IFN-alpha was successful in ou
r patient in controlling myeloproliferation and stabilizing the diseas
e over a prolonged period. These results support the use of IFN-alpha,
not only as a means of myelosuppression in PRV but also as an agent w
ith the potential to prevent disease progression.